News

III/IV resectable melanoma remained event-free at four years from the start of neoadjuvant systemic treatment.
The CRL was given because the FDA did not consider the phase 1/2 IGNYTE trial to be an adequate and well-controlled clinical ...
Designing a High-Sensitivity Microscale Triple-Band Biosensor Based on Terahertz MTMs to Provide a Perfect Absorber for Non-Melanoma Skin Cancer Diagnostic ...
Melanoma testing could one day be done at home with a skin patch and test strip with two lines, similar to COVID-19 home ...
Adding SCIB1 or iSCIB1+ to standard treatments helped more patients with advanced melanoma respond and live longer without ...
The FDA cited trial design concerns and lack of substantial evidence in denying approval for Replimune’s biologics license application in advanced melanoma.